Genetic Predictors of Prostate Cancer Survival
Genetic Predictors of Prostate Cancer Survival
批准号:
10533696
负责人:
ROBERT J. KLEIN
金额:
$6.82万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-01-15 至 2025-12-31
关键词:
AfricanAreaBiologicalClinicalDataDatabasesDevelopmentDiabetes MellitusDiagnosisDiseaseEpidemiologyFundingGeneticGenomicsGrantHealth Services AccessibilityHealth systemIndolentK-Series Research Career ProgramsKnowledgeLeadLinkMalignant neoplasm of prostateManuscriptsMendelian randomizationNative-BornNon-Insulin-Dependent Diabetes MellitusObesityOperative Surgical ProceduresParentsPatternPreparationRaceResearchRiskRisk FactorsSeriesSingle Nucleotide PolymorphismSiteStatistical Data InterpretationTestingVeterans Health AdministrationWorkbasecancer survivalcareercareer developmentcourse developmentepidemiologic datagenetic analysisgenetic predictorsmenmortalitynovelparent grantprostate cancer riskrisk stratificationscreeningskills
中文摘要
前列腺癌(PC)具有非常异质性的临床病程。很多男人的电脑都是懒洋洋的
英文摘要
Prostate cancer (PC) has a very heterogenous clinical course. Many men have an indolent PC that can be
safely watched for years without progression. Alternatively, other men have an aggressive form of PC and can
progress very rapidly. Understanding PC risk stratification and separating indolent from aggressive disease is a
crucial unmet clinical need. Increasing data suggest that genetic single nucleotide polymorphisms (SNPs) may
aid in this effort. Indeed, this is the fundamental basis of the parent R01 (Klein PI; Freedland site PI).
In line with that overarching view, this supplement supports Dr. Asilonu's development to focus on two areas
of risk stratification: 1) Using genetic SNP data; 2) using epidemiological data (obesity and diabetes status).
In Aim 1, we aim to build upon our genetic analyses proposed in the parent grant. Specifically, we will use
Mendelian Randomization (MR) to determine causal relationships between type 2 diabetes and obesity with
prostate cancer survival. Building upon recent work classifying type 2 diabetes into different subtypes, we will
ask use genetic predictors of these diabetes subtypes, as well as predictors of obesity, as instrumental variables
in the Mendelian Randomization analysis. By comparing the effect size of SNPs on these variabes with the
effect size of these same SNPs on prostate cancer survival (derived from data from the parent grant), we will
determine the extent to which these subtypes of diabetes and obesity directly lead to worse prostate cancer
survival.
In Aim 2, we will build upon the novel finding by Dr. Freedland and his team that diabetes and obesity appear
to act synergistically to create a more aggressive PC. This was not seen for overall PC risk, but specifically for
aggressive PC. This synergistic interaction was noted for both diagnosis of high-grade PC and PC mortality after
surgery for early-stage disease. Based upon these findings, we hypothesize that diabetes and obesity will
interact to synergistically increase the risk of aggressive PC (high-grade PC and PC mortality) but not low-grade
PC. We further hypothesize these associations will be independent of screening patterns and access to care
suggesting a biological basis. We will test this hypothesis using nationwide data from the Veterans Affairs (VA)
Health System. We received a separate grant to create a nationwide database to study the potential link between
obesity and race in predicting aggressive PC. The vast majority of work for this other grant is now complete. This
creates a great opportunity for Dr. Asilonu to build upon his current statistical knowledge and complete the
complicated analyses proposed in this supplement.
From the research proposed, Dr. Asilonu will develop new skills in advanced statistical analyses, genetic
analyses, working with nationwide data, and manuscript preparation. We also built-in didactic work to help him
prepare grants. At the end of the nearly 3-year supplement, not only will we have answered key questions in the
field, but he will be ready to take the next step in his career – applying for a K-award or R-series grant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic predictors of prostate cancer survival
-
批准号:10599501
-
项目类别:
-
资助金额:$10.91万
-
财政年份:2021
-
负责人:ROBERT J. KLEIN
-
依托单位:
Genetic Predictors of Prostate Cancer Survival
-
批准号:10408510
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2021
-
负责人:ROBERT J. KLEIN
-
依托单位:
Genetic Predictors of Prostate Cancer Survival
-
批准号:10330024
-
项目类别:
-
资助金额:$69.47万
-
财政年份:2021
-
负责人:ROBERT J. KLEIN
-
依托单位:
Genetic Predictors of Prostate Cancer Survival
-
批准号:10580599
-
项目类别:
-
资助金额:$68.88万
-
财政年份:2021
-
负责人:ROBERT J. KLEIN
-
依托单位:
Genetic Predictors of Prostate Cancer Survival
-
批准号:10759024
-
项目类别:
-
资助金额:$22.26万
-
财政年份:2021
-
负责人:ROBERT J. KLEIN
-
依托单位:
Integrated high-throughput functional assays to identify ulcerative colitis causal risk variants
-
批准号:9918930
-
项目类别:
-
资助金额:$65.72万
-
财政年份:2018
-
负责人:ROBERT J. KLEIN
-
依托单位:
Integrated high-throughput functional assays to identify ulcerative colitis causal risk variants
-
批准号:10391446
-
项目类别:
-
资助金额:$65.71万
-
财政年份:2018
-
负责人:ROBERT J. KLEIN
-
依托单位:
Integrated high-throughput functional assays to identify ulcerative colitis causal risk variants
-
批准号:9752313
-
项目类别:
-
资助金额:$66.07万
-
财政年份:2018
-
负责人:ROBERT J. KLEIN
-
依托单位:
Improving prostate cancer screening by integration of SNPs with blood biomarkers
-
批准号:8628820
-
项目类别:
-
资助金额:$49.62万
-
财政年份:2013
-
负责人:ROBERT J. KLEIN
-
依托单位:
Improving prostate cancer screening by integration of SNPs with blood biomarkers
-
批准号:8483122
-
项目类别:
-
资助金额:$51.15万
-
财政年份:2013
-
负责人:ROBERT J. KLEIN
-
依托单位:
Improving prostate cancer screening by integration of SNPs with blood biomarkers
-
批准号:9318455
-
项目类别:
-
资助金额:$57.54万
-
财政年份:2013
-
负责人:ROBERT J. KLEIN
-
依托单位:
Improving prostate cancer screening by integration of SNPs with blood biomarkers
-
批准号:8969796
-
项目类别:
-
资助金额:$61.44万
-
财政年份:2013
-
负责人:ROBERT J. KLEIN
-
依托单位:
Identification of regulatory cancer risk SNPs for chemoprevention discovery
-
批准号:8521206
-
项目类别:
-
资助金额:$8.6万
-
财政年份:2012
-
负责人:ROBERT J. KLEIN
-
依托单位:
Linking disease-associated variants to transcriptional regulation using ENCODE
-
批准号:8691952
-
项目类别:
-
资助金额:$50.3万
-
财政年份:2012
-
负责人:ROBERT J. KLEIN
-
依托单位:
Identification of regulatory cancer risk SNPs for chemoprevention discovery
-
批准号:8242213
-
项目类别:
-
资助金额:$9.15万
-
财政年份:2012
-
负责人:ROBERT J. KLEIN
-
依托单位:
Linking disease-associated variants to transcriptional regulation using ENCODE
-
批准号:9090935
-
项目类别:
-
资助金额:$36.21万
-
财政年份:2012
-
负责人:ROBERT J. KLEIN
-
依托单位:
Linking disease-associated variants to transcriptional regulation using ENCODE
-
批准号:8546275
-
项目类别:
-
资助金额:$52.68万
-
财政年份:2012
-
负责人:ROBERT J. KLEIN
-
依托单位:
Linking disease-associated variants to transcriptional regulation using ENCODE
-
批准号:8402495
-
项目类别:
-
资助金额:$50.58万
-
财政年份:2012
-
负责人:ROBERT J. KLEIN
-
依托单位:
Are shared controls useful in genome-wide association studies for cancer genetic
-
批准号:7741023
-
项目类别:
-
资助金额:$9.48万
-
财政年份:2009
-
负责人:ROBERT J. KLEIN
-
依托单位:
Are shared controls useful in genome-wide association studies for cancer genetic
-
批准号:7897938
-
项目类别:
-
资助金额:$9.48万
-
财政年份:2009
-
负责人:ROBERT J. KLEIN
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: